Real-world efficacy and safety of efgartigimod in patients with autoimmune encephalitis: a single-center retrospective analysiss
- 1Department of Neurology, The Second Hospital of Hebei Medical University
- 2Key Laboratory of Neurology of Hebei Province, The Second Hospital of Hebei Medical University
- 3Department of Encephalopathy, Hebei University of Chinese Medicine Hebei Provincial Hospital of Traditional Chinese
Abstract
Objective: This study was conducted to evaluate the efficacy and safety of efgartigimod (EFG), a neonatal Fc receptor (FcRn) antagonist, in the treatment of autoimmune encephalitis (AE) under real-world conditions and to provide clinical evidence for treating AE patients who respond poorly to first-line and/or second-line immunotherapy.
Methods: In this study, clinical data of 14 AE patients who were treated with EFG at the Department of Neurology, The Second Hospital of Hebei Medical University between November 2023 and November 2025 were retrospectively analyzed. Treatment efficacy, disease prognosis, and adverse reactions were assessed.
Results: In total, 14 AE patients were included, 11 with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, and one each with anti-metabotropic glutamate receptor 5 (mGluR5) antibody-associated encephalitis, anti-leucine-rich glioma-inactivated protein 1 (LGI1) antibody-associated encephalopathy, and anti-IgLON family protein 5 (IgLON5) antibody-associated encephalopathy. The baseline median Modified Rankin Scale (mRS) score was 3.00 (3.00, 4.00), and the baseline median Clinical Assessment Scale for Autoimmune Encephalitis (CASE) score was 5.00 (4.25, 12.75). After EFG treatment, both mRS and CASE scores decreased significantly at all follow-up time points (Friedman test, P< 0.05). By week 12, 92.86% of patients achieved a favorable functional outcome (mRS ≤ 2). Clinical Global Impressions (CGI) scores indicated that most patients experienced clinically meaningful overall improvement, consistent with the improvements observed in the above scores. The Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score suggested that the overall prognosis of patients was satisfactory, and no relapses occurred during follow-up. Regular monitoring of peripheral blood immunoglobulin G (IgG) levels in nine patients showed a marked reduction at one week and three weeks after EFG treatment compared to baseline levels. The levels were higher at 12 weeks compared to those in the third week, although the levels remained below baseline. No patient required treatment discontinuation due to severe adverse reactions throughout the course of treatment.
Conclusion: When AE patients with poor response to first-line and/or second-line immunotherapy were administered EFG treatment, they showed rapid and significant clinical improvement, favorable prognosis, and few adverse reactions. However, the long-term efficacy and safety of EFG require validation in multicenter, large-sample studies.
Related
- Efficacy and safety of acute-phase immunotherapy for adult autoimmune encephalitis: a systematic review and network meta-analysis
- Clinical features and long-term outcomes of anti-DPPX autoimmune encephalitis: a multicentre retrospective study in a Chinese cohort.
- Efgartigimod-responsive autoimmune peripheral neuropathy with concurrent anti-GM2 IgG and anti-contactin-1 IgG antibodies: a rare case report.
- Safety and efficacy of intrathecal methotrexate in severe anti-NMDAR encephalitis: a single-institution retrospective study
- AI-Assisted Tissue-Based Antibody Interpretation in Autoimmune Encephalitis: Prospective Validation and Reader Study
BibTeX
@article{song2026realworld,
title = {{Real-world efficacy and safety of efgartigimod in patients with autoimmune encephalitis: a single-center retrospective analysiss}},
author = {Zhijiao Song and Lantao Liang and Meiling Zhang and Yu Zhang and Hui Bu and Yanbo Zhang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1963052},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1963052/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world efficacy and safety of efgartigimod in patients with autoimmune encephalitis: a single-center retrospective analysiss
AU - Zhijiao Song
AU - Lantao Liang
AU - Meiling Zhang
AU - Yu Zhang
AU - Hui Bu
AU - Yanbo Zhang
PY - 2026
DA - 2026/10/08
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1963052
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1963052/full
AB - Objective: This study was conducted to evaluate the efficacy and safety of efgartigimod (EFG), a neonatal Fc receptor (FcRn) antagonist, in the treatment of autoimmune encephalitis (AE) under real-world conditions and to provide clinical evidence for treating AE patients who respond poorly to first-line and/or second-line immunotherapy. Methods: In this study, clinical data of 14 AE patients who were treated with EFG at the Department of Neurology, The Second Hospital of Hebei Medical University between November 2023 and November 2025 were retrospectively analyzed. Treatment efficacy, disease prognosis, and adverse reactions were assessed. Results: In total, 14 AE patients were included, 11 with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, and one each with anti-metabotropic glutamate receptor 5 (mGluR5) antibody-associated encephalitis, anti-leucine-rich glioma-inactivated protein 1 (LGI1) antibody-associated encephalopathy, and anti-IgLON family protein 5 (IgLON5) antibody-associated encephalopathy. The baseline median Modified Rankin Scale (mRS) score was 3.00 (3.00, 4.00), and the baseline median Clinical Assessment Scale for Autoimmune Encephalitis (CASE) score was 5.00 (4.25, 12.75). After EFG treatment, both mRS and CASE scores decreased significantly at all follow-up time points (Friedman test, P< 0.05). By week 12, 92.86% of patients achieved a favorable functional outcome (mRS ≤ 2). Clinical Global Impressions (CGI) scores indicated that most patients experienced clinically meaningful overall improvement, consistent with the improvements observed in the above scores. The Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score suggested that the overall prognosis of patients was satisfactory, and no relapses occurred during follow-up. Regular monitoring of peripheral blood immunoglobulin G (IgG) levels in nine patients showed a marked reduction at one week and three weeks after EFG treatment compared to baseline levels. The levels were higher at 12 weeks compared to those in the third week, although the levels remained below baseline. No patient required treatment discontinuation due to severe adverse reactions throughout the course of treatment. Conclusion: When AE patients with poor response to first-line and/or second-line immunotherapy were administered EFG treatment, they showed rapid and significant clinical improvement, favorable prognosis, and few adverse reactions. However, the long-term efficacy and safety of EFG require validation in multicenter, large-sample studies.
SN - 1664-3224
ER -